Morphofunctional analysis of human pancreatic cancer cell lines in 2- and 3-dimensional cultures.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Biomarkers, Tumor* ; Cell Culture Techniques* ; Cell Line, Tumor* ; Spheroids, Cellular*; Antineoplastic Agents/pharmacology ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Gene Expression Profiling ; Humans ; Immunohistochemistry ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/ultrastructure

Genetic, transcriptional, and morphological differences have been reported in pancreatic ductal adenocarcinoma (PDAC) cases. We recently found that epithelial or mesenchymal features were enhanced in three-dimensional (3D) cultures compared to two-dimensional (2D) cultures. In this study, we examined the differences in the morphological and functional characteristics of eight PDAC cell lines in 2D and 3D cultures. Most PDAC cells showed similar pleomorphic morphologies in 2D culture. Under 3D culture, PDAC cells with high E-cadherin and low vimentin expression levels (epithelial) formed small round spheres encircled with flat lining cells, whereas those with high vimentin and low E-cadherin expression levels (mesenchymal) formed large grape-like spheres without lining cells and were highly proliferative. In 3D culture, gemcitabine was more effective for the spheres formed by PDAC cells with epithelial features, while abraxane was more effective on those with mesenchymal features. The expression levels of drug transporters were highest PDAC cells with high vimentin expression levels. These findings indicate that PDAC cells possess various levels of epithelial and mesenchymal characteristics. The 3D-culture method is useful for investigating the diversity of PDAC cell lines and may play important roles in the development of personalized early diagnostic methods and anticancer drugs for PDAC.

Am J Transl Res. 2019 Jul 15;11(7):3932-3944. (PMID: 31396310)
Biochem Biophys Res Commun. 2020 Feb 19;522(4):881-888. (PMID: 31806369)
J Hepatobiliary Pancreat Surg. 2007;14(3):224-32. (PMID: 17520196)
Best Pract Res Clin Gastroenterol. 2017 Oct;31(5):529-536. (PMID: 29195672)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
Int J Cancer. 1977 Jan;19(1):128-35. (PMID: 832918)
Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647)
Oncotarget. 2018 Oct 5;9(78):34719-34734. (PMID: 30410672)
Sci Rep. 2019 Dec 18;9(1):19369. (PMID: 31852956)
Oncol Lett. 2018 Feb;15(2):2485-2490. (PMID: 29434962)
Pathol Oncol Res. 2018 Oct;24(4):797-805. (PMID: 29948612)
Int J Cancer. 1975 May 15;15(5):741-7. (PMID: 1140870)
Sci Rep. 2019 Jul 26;9(1):10871. (PMID: 31350453)
Cells Tissues Organs. 2007;185(1-3):20-8. (PMID: 17587804)
Oncogenesis. 2017 Sep 18;6(9):e378. (PMID: 28920928)
Biochem Biophys Res Commun. 2019 Jun 18;514(1):112-117. (PMID: 31027735)
Int J Mol Sci. 2019 Sep 10;20(18):. (PMID: 31510100)
Sci Rep. 2016 Feb 17;6:21648. (PMID: 26884312)
Cancer Sci. 2018 Apr;109(4):1135-1146. (PMID: 29444383)
Radiat Oncol. 2019 Aug 8;14(1):141. (PMID: 31395068)
Nat Rev Dis Primers. 2016 Apr 21;2:16022. (PMID: 27158978)
Cell. 2007 Aug 24;130(4):601-10. (PMID: 17719539)
Virchows Arch. 2001 Dec;439(6):798-802. (PMID: 11787853)
Tohoku J Exp Med. 1986 Nov;150(3):231-48. (PMID: 3547771)
Int J Oncol. 1994 Jul;5(1):33-9. (PMID: 21559554)
Tohoku J Exp Med. 1984 May;143(1):33-46. (PMID: 6205469)
Nat Med. 2011 Apr;17(4):500-3. (PMID: 21460848)
J Gastrointest Oncol. 2011 Sep;2(3):126-35. (PMID: 22811842)
Cancer Res. 2007 Apr 1;67(7):3094-105. (PMID: 17409416)
Lab Invest. 2018 Jun;98(6):814-824. (PMID: 29581580)
Int J Pancreatol. 1995 Apr;17(2):139-46. (PMID: 7622937)
Cancer. 1983 Feb 15;51(4):662-8. (PMID: 6821838)
Oncol Rep. 2001 Jan-Feb;8(1):89-92. (PMID: 11115575)
J Cell Physiol. 2000 Mar;182(3):311-22. (PMID: 10653597)
Pancreatology. 2019 Jan;19(1):88-96. (PMID: 30416041)

0 (Antineoplastic Agents)
0 (Biomarkers, Tumor)

Date Created: 20210325 Date Completed: 20211022 Latest Revision: 20211022

20240829

PMC7990961

10.1038/s41598-021-86028-1

33762591